Copilot
Your everyday AI companion
About 77,500 results
Open links in new tab
  2. People also ask
    Does Patritumab deruxtecan meet the primary endpoint of progression-free survival?
    D aiichi Sankyo and MSD  (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd antibody-drug conjugate (ADC) in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), met the primary endpoint of progression-free survival (PFS).

    Daiichi Sankyo and MSD’s ADC improves progression-free survival in N…

    msn.com
    Does Merck MRK's Patritumab deruxtecan treat EGFR-mutated non-small cell lung?
    Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer (NSCLC), met its primary endpoint of progression-free survival (PFS).

    Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

    msn.com
    Does Merck own mk-1022 and ifinatamab deruxtecan?
    Merck acquired global co-development and co-commercialization rights to patritumab deruxtecan/MK-1022 and two other ADCs, raludotatug deruxtecan/MK-5909 and ifinatamab deruxtecan/MK-2400 from Japan’s Daiichi Sankyo in October last year for a total potential consideration of up to $22 billion.

    Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

    msn.com
    What is the difference between raludotatug and ifinatamab deruxtecan?
    While raludotatug deruxtecan is being developed in phase II/III study for ovarian cancer, ifinatamab deruxtecan is being studied for small-cell lung cancer in phase III and colorectal, bladder, endometrial and head and neck cancers in phase II. Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.

    Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

    msn.com
    Feedback
  3. Daiichi Sankyo US
    https://daiichisankyo.us/press-releases/-/article/...

    Patritumab Deruxtecan Demonstrated Statistically Significant ...

  5. Merck
    https://www.merck.com/news/patritumab-deruxtecan...

    Patritumab Deruxtecan Demonstrated Statistically Significant

  6. OncLive
    https://www.onclive.com/view/patritumab-deruxtecan...

    Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR …

  8. Daiichi Sankyo US
    https://daiichisankyo.us/press-releases/-/article/...

    Patritumab Deruxtecan BLA Submission Receives Complete …

    Tags:
    Daiichi Sankyo
    Third party
  9. Merck
    https://www.merck.com/news/patritumab-deruxtecan...

    Patritumab Deruxtecan Granted Priority Review in the U.S. for

    Tags:
    Non-small cell lung cancer
    Canadian Parliamentary Review
  10. Daiichi Sankyo
    https://www.daiichisankyo.com/files/news/press...
    [PDF]

    Press Release - Daiichi Sankyo

    Tags:
    Non-small cell lung cancer
    Daiichi Sankyo
    Press release
  11. Healio
    https://www.healio.com/news/hematology-oncology/...

    Patritumab deruxtecan extends PFS vs. chemotherapy in advanced …

    Tags:
    Non-small cell lung cancer
    Patritumab
  12. Daiichi Sankyo
    https://www.daiichisankyo.com/files/news/press...
    [PDF]

    Press Release - Daiichi Sankyo

    Tags:
    Daiichi Sankyo
    Press release
  13. FT.com
    https://markets.ft.com/data/announce/detail?dockey=...

    Patritumab Deruxtecan Demonstrated Statistically Significant ...

    Tags:
    Non-small cell lung cancer
    Daiichi Sankyo
  14. Clinical Trials Arena
    https://www.clinicaltrialsarena.com/news/daiichi-sankyo-msd-nsclc-trial

    Daiichi Sankyo-MSD’s ADC improves survival in NSCLC trial

    Tags:
    Non-small cell lung cancer
    Daiichi Sankyo
  16. Some results have been removed